Clinical Trials Logo
  1. Home
  2. Drug Safety
  3. NCT01501968
  4. Details
NCT01501968 Clinical Trial

Efficacy of Ascorbic Acid for Prevention of Colistin-Associated Nephrotoxicity

Drug Safety Clinical Trial

Official title:
Efficacy of Ascorbic Acid for Prevention of Colistin-Associated Nephrotoxicity

Clinical Trial Details — Status: Not yet recruiting

Administrative data
NCT number NCT01501968
Other study ID # CEU 2012-01
Secondary ID
Status Not yet recruiting
Phase Phase 3
First received December 24, 2011
Last updated December 29, 2011
Start date January 2012
Est. completion date December 2013

Study information
Verified date December 2011
Source Mahidol University
Contact Visanu Thamlikitkul, MD
Phone 662-419-7783
Email sivth@mahidol.ac.th
Is FDA regulated No
Health authority Thailand: Ethical Committee
Study type Interventional

Clinical Trial Summary

Ascorbic acid (Vitamin C) could protect renal toxicity from colistin.

Description:

Renal toxicity due to colistin therapy is common. Ascorbic acid (vitamin C) has been shown to prevent colistin associated renal toxicity in animals. This study is conducted to determine if acorbic acid can prevent Colistin-Associated Nephrotoxicity.

Recruitment information / eligibility
Status Not yet recruiting
Enrollment 54
Est. completion date December 2013
Est. primary completion date December 2013
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria:

- age > 18 years hospitalized patient who needs colistin for therapy of nosocomial infection

Exclusion Criteria:

- pregnant woman

- lactating mother

- allergy to ascorbic acid

- receiving non-steroidal antiinflammatory drugs (NSAID), aminoglycosides, vancomycin, cisplatin, amphotericin-B

- received radiocontrast media within 1 week

- renal stone

- G-6-PD deficiency

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention

Related Conditions & MeSH terms

Intervention

Drug:
• Colistin
Colistimethate sodium 2.5-5mg/kg iv per day
• Colistin + Ascorbic acid
Colistimethate sodium 2.5-5mg/kg iv per day and ascorbic acid 2 grams iv q 12 hours

Locations
Country Name City State
Thailand Siriraj Hospital Bangkok

Sponsors (2)
Lead Sponsor Collaborator
Mahidol University Siriraj Hospital

Country where clinical trial is conducted

Thailand, 

Outcome
Type Measure Description Time frame Safety issue
Primary number of patients with Renal toxicity associated with colistin Renal toxicity associated with colistin according to RIFLE criteria up to 28 days Yes
Secondary number of subjects with cure or improvement cure improvement worse death up to 28 days Yes
See also
  Status Clinical Trial Phase
Completed NCT01425502 - Data-driven Quality Improvement in Primary Care - Trial N/A
Recruiting NCT01756183 - Exploratory Study on the S-1 + Paclitaxel Chemotherapy for Unresectable Gastric Cancer Phase 2
Completed NCT01355016 - A Trial to Assess the Safety, Tolerability, and Pharmacokinetics of MDT-637 in Healthy Volunteers Phase 1
Completed NCT01757860 - Safety and Pharmacokinetics Study of CARD-024 in Healthy Subjects Phase 1
Completed NCT01179854 - Remegal Different Doses in Patients With Refractory Partial Seizures Phase 2
Completed NCT00376415 - A Safety Study of Lessertia Frutescens in Adults. Phase 1
Active, not recruiting NCT01722916 - Reducing and Removing Hyaluronic Acid Filler With Hyaluronidase Early Phase 1
Completed NCT01727778 - Safety and Preliminary Efficacy Study of the Antibody PAT-SM6 in Patients With Relapsed or Refractory Multiple Myeloma Phase 1
Completed NCT01475097 - Comparing Patient Comfort and Safety Between Iodixanol and Iopamidol in Patients Undergoing Peripheral Arteriography Phase 4
Completed NCT01412658 - Clinical Safety of a Novel Milk Protein Peptide Phase 1
Terminated NCT01847222 - An Assessment of the Safety and Pharmacokinetics of Ascending Doses of SANGUINATE™ in Healthy Volunteers. Phase 1
Unknown status NCT01633099 - Therapeutic Effect and Safety Study of Decitabine in Elderly Acute Myeloid Leukemia Patients Phase 3
Recruiting NCT01297842 - Ertapenem Versus Meropenem/Imipenem for ESBL+ Gram-negative Infections Phase 4
Completed NCT01284582 - Safety, Immunogenicity and Dose Response of ATH03, a New Vaccine Against the Cholesterol Ester Transfer Protein (CETP) Phase 1
Completed NCT01557270 - Efficacy and Safety Study of Dexmedetomidine as an Additive to Local Anesthetics in Shoulder Surgery Phase 3
Completed NCT01556607 - A Trial to Assess the Safety, Tolerability and Pharmacokinetics of MDT-637 in Subjects With Intermittent, or Mild-to-Moderate Persistent, Asthma Phase 1
Completed NCT01319903 - Clinical Assessment of Safety and Tolerability of the New Monoclonal Humanized Antibody CaCP29 Phase 1
Completed NCT01271569 - A Study to Assess the Efficacy and Safety of Fospropofol Disodium Phase 1
Recruiting NCT04785027 - Comparison of PSORI-CM01 Formula vs Gu Ben Hua Yu Formula Combined With AD-MSCs in Psoriasis Phase 1/Phase 2
Completed NCT01367873 - Ascending Single-Dose Study to Evaluate VIA-3196 in Healthy Subjects Phase 1

External Links